Ondine Biomedical (FRA:VF5) Retained Earnings : €-185.80 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Ondine Biomedical's retained earnings for the quarter that ended in Jun. 2024 was €-185.80 Mil.

Ondine Biomedical's quarterly retained earnings declined from Jun. 2023 (€-180.50 Mil) to Dec. 2023 (€-182.04 Mil) and declined from Dec. 2023 (€-182.04 Mil) to Jun. 2024 (€-185.80 Mil).

Ondine Biomedical's annual retained earnings declined from Dec. 2021 (€-160.78 Mil) to Dec. 2022 (€-175.06 Mil) and declined from Dec. 2022 (€-175.06 Mil) to Dec. 2023 (€-182.04 Mil).

Ondine Biomedical Retained Earnings Historical Data

The historical data trend for Ondine Biomedical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Retained Earnings Chart

Ondine Biomedical Annual Data

Trend

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-113.36

-116.88

-160.78

-175.06

-182.04

Ondine Biomedical Semi-Annual Data
	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Retained Earnings	Get a 7-Day Free Trial															-178.14	-175.06	-180.50	-182.04	-185.80

Ondine Biomedical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Ondine Biomedical (FRA:VF5) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Ondine Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (FRA:VF5) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

OBIMF:USA OBI:UK

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical Headlines

No Headlines